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Breast cancer progression involves cancer cell he-
terogeneity, with generation of invasive/metastatic
breast cancer cells within populations of nonmeta-
static cells of the primary tumor. Sequential genetic
mutations, epithelial-to-mesenchymal transition, in-
teraction with local stroma, and formation of hybrids
between cancer cells and normal bone marrow–
derived cells have been advocated as tumor progres-
sion mechanisms. We report herein the spontaneous
in vitro formation of heterotypic hybrids between hu-
man bone marrow–derived multipotent stromal cells
(MSCs) and two different breast carcinoma cell lines,
MDA-MB-231 (MDA) and MA11. Hybrids showed pre-
dominantly mesenchymal morphological character-
istics, mixed gene expression profiles, and increased
DNA ploidy. Both MA11 and MDA hybrids were tu-
morigenic in immunodeficient mice, and some MDA
hybrids had an increased metastatic capacity. Both in
culture and as xenografts, hybrids underwent DNA
ploidy reduction and morphological reversal to
breast carcinoma–like morphological characteristics,
while maintaining a mixed breast cancer–mesenchy-
mal expression profile. Analysis of coding single-nu-
cleotide polymorphisms by RNA sequencing revealed
genetic contributions from both parental partners to
hybrid tumors and metastasis. Because MSCs migrate
and localize to breast carcinoma, our findings indi-
cate that formation of MSC–breast cancer cell hy-
brids is a potential mechanism of the generation of
invasive/metastatic breast cancer cells. Our find-
ings reconcile the fusion theory of cancer progres-
sion with the common observation that breast can-
cer metastases are generally aneuploid, but not
tetraploid, and are histopathologically similar to
the primary neoplasm. (Am J Pathol 2012, 180:2504–
2515; http://dx.doi.org/10.1016/j.ajpath.2012.02.020)
2504Although clonal in origin, breast carcinomas display con-
siderable cell heterogeneity, with intratumoral diversity
already apparent at the stage of ductal carcinoma in
situ.1,2 The generation of cell subpopulations exhibiting
cytogenetic abnormalities, along with invasive/prometa-
static features, is inherent to breast cancer progression.
Unknown triggers enable some of these cells to break
free from the primary tumor, invade the microvasculature,
travel, and establish foci at distant sites. Their actual
genesis from within populations of nonmetastatic cells of
the primary tumor has not yet been clarified. A stochastic
mutation of key genes, epithelial-mesenchymal transition
(EMT),3,4 and influence of stromal microenvironment at
the tumor boundary5–7 have been proposed as underly-
ing mechanisms of breast cancer progression. However,
how successive, stepwise mutations of many key genes,
necessary for the generation of a metastatic phenotype,
might occur in sufficient numbers to overcome the ineffi-
ciency of the metastatic process itself is unclear.8 Also,
the histopathological similarity of metastases to the pri-
mary tumor argues against the EMT theory. A subsequent
step, mesenchymal-epithelial transition,9,10 occurring at
the metastatic sites, or the possible cooperation between
EMT and non-EMT cancer cells11 may resolve this ap-
parent contradiction. The formation of hybrids between
cancer cells and normal bone marrow–derived cells, in-
cluding mesenchymal stem cells or multipotent stromal
cells (MSCs), within tumor-associated stroma has been
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contribute to aneuploidy and aberrant gene expression
patterns associated with highly malignant subpopula-
tions.12–20 However, this theory has encountered much
skepticism, mainly because, in most cases, recurrent and
metastatic tumors have similar histopathological features
as the primary neoplasm and tetraploid metastatic cells
are rare. Herein, we show that high-ploidy hybrids with
predominantly mesenchymal morphological characteris-
tics, spontaneously formed between human breast can-
cer cells and MSCs, reacquire, in culture and as xeno-
grafts, a ploidy similar to that of the respective parental
breast cancer cell line and form tumors histopathologi-
cally similar to the original breast carcinoma, while ac-
quiring and maintaining expression of mesenchymal
genes.
Materials and Methods
Cell Lines
Human MDA-MB-231 (MDA) breast cancer cells were
obtained from the ATCC (Manassas, VA) in 2007. The
human MA11 breast carcinoma cell line, established from
bone marrow micrometastases of a patient with breast
cancer,21,22 was obtained by Øystein Fodstad (Norwe-
gian Radium Hospital, Oslo, Norway) in 2006. Both breast
cancer cell lines were used in this study between pas-
sages 20 and 30. Breast cancer cells were cultured in
RPMI 1640 medium (Gibco, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (Atlanta Biologicals,
Inc., Norcross, GA), 100 U/mL penicillin, 100 g/mL
streptomycin, and 2 mmol/L L-glutamine. Human MSCs
were obtained from Darwin Prockop in 2008. They were
isolated from 1- to 4-mL bone marrow aspirates taken
from the iliac crest of normal adult donors after informed
consent and under a protocol approved by the Tulane
University Institutional Review Board, prepared as de-
scribed by Larson et al,23 and frozen at passage 1. For
expansion, MSCs were plated in a 75-cm2 culture dish
and incubated for 1 day, to recover viable adherent cells.
Cultures contained approximately 50% of rapidly self-
renewing cells and 50% of larger, more slowly dividing
and more mature cells. MSCs were then replated at 50
cells/cm2 and incubated for 10 days before lentiviral
transduction. With time in culture, the percentage of rap-
idly self-renewing cells decreased progressively to
10% of the total cells. All cell lines were stored in ali-
quots in liquid nitrogen and kept in culture for3 months.
Complete culture medium for MSCs consisted of -min-
imal essential medium (Gibco), 17% fetal bovine serum
(lot selected for rapid growth of MSCs) (Atlanta Biologi-
cals), 100 U/mL penicillin, 100 g/mL streptomycin, and
2 mmol/L L-glutamine. All cells were tested for Myco-
plasma contamination every 6 months and authenticated
by a morphological check every 2 weeks.
Fluorescence Microscopy
Confocal images were taken using a homebuilt multipho-
ton microscope. The excitation wavelength was at 924nm. The epireflected emission signals arising from en-
hanced green fluorescence protein (EGFP) and DsRed
were collected simultaneously with 500/40-nm and 600/
40-nm bandpass filters, respectively. Immunostaining for
EGFP on tissue sections, after deparaffinization and boil-
ing in 0.01 mol/L citric acid (pH 6) for antigen retrieval,
was performed by overnight 4°C incubation with fluores-
cein isothiocyanate–EGFP antibody (1:500; GeneTex,
San Antonio, TX) in 1% bovine serum albumin–PBS.
Retroviral and Lentiviral Vectors
The EGFP- and DsRed-expressing retroviral vectors used
are based on pSF91 (GenBank accession number
AJ224005) with the 3= long terminal repeat of spleen
focus-forming virus and the leader of the murine embry-
onic stem cell virus.24,25 To generate retroviral produc-
ers, the Phoenix-gp packaging cell line was transfected
with pSF91-DsRed, or pSF91-EGFP, and a plasmid ex-
pressing the vesicular stomatitis virus glycoprotein. Cul-
ture supernatants containing viral particles were col-
lected at 24 to 48 hours after transfection, passed
through 0.22-m Millex GP filters (Millipore Co, Bedford,
MA), and stored at -80°C. For transduction, retroviral
supernatants were preloaded onto recombinant fibronec-
tin (Retronectin; Takara Shuzo, Kyoto, Japan) coated
plates and centrifuged at 950  g for 30 minutes at 4°C.
The operation was repeated a second time with fresh
supernatant. The supernatant was then removed, and the
plates were washed with PBS before the addition of
cells. After transduction, stable cell lines were isolated
via selection with 2 g/mL puromycin. A few days later,
cells were cloned by limiting dilution. MSCs were trans-
duced with vesicular stomatitis virus–pseudotyped len-
tiviral particles constitutively expressing firefly lucifer-
ase (luc) under the control of the cytomegalovirus
promoter and the puromycin N-acetyltransferase (pac)
gene under the control of the human phosphoglycerate
kinase promoter (pCignal-luc) (SA Biosciences, Fred-
erick, MD), using the fibronectin (Retronectin) method,
as previously described. Transduced cells were iso-
lated via selection with 2 g/mL puromycin.
Wound-Healing Assay
Cell motility was measured by a conventional wound-
healing assay.26 Briefly, 20,000 cells per well were plated
in RPMI 1640 medium supplemented with 10% fetal bo-
vine serum in polystyrene tissue culture-treated six-well
plates. After 24 hours, medium was gently aspirated,
wounds were generated by yellow tips with constant
pressure, and prewarmed (37°C) RPMI 1640 medium
supplemented with 1% fetal bovine serum was added. At
indicated times, the same areas of each wound were
sequentially imaged.
Invasion Assays
In vitro invasion assays were performed in BioCoat invasion
chambers with Matrigel-coated positron emission tomo-
graphic membrane cell culture inserts (8-m pore), using
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San Jose, CA), according to the manufacturer’s directions.
The Matrigel layers of the invasion chambers were rehy-
drated with serum-free -minimal essential medium. The
lower chambers were filled with -minimal essential me-
dium containing 5% fetal bovine serum, and equal numbers
of cells in serum-free -minimal essential medium were
added to every insert. After a 24-hour incubation at 37°C,
the cells on the upper side of the membrane were gently
removed with wet cotton swabs. The cells on the lower
surface of the membranes were fixed with 4% paraformal-
dehyde for 10 minutes and then stained with DAPI. The
number of cells was counted in 8 to 12 randomly selected
microscopic fields per insert (original magnification, 100)
using an Olympus CKX41 fluorescence microscope (Olym-
pus America Corp, Center Valley, PA). To measure inva-
siveness, the cells that migrated through the Matrigel mem-
branes were counted and expressed as percentage of cells
migrated through control insert membranes.
Drug Sensitivity Assay
Puromycin resistance was determined using the methyl-
ated tetrazolium salt/phenazine methosulfate microtiter
plate assay, as previously described.27
Flow Cytometric Analysis
DNA and marker analyses were performed using an iCyt
Reflection flow cytometer (iCyt, Champaign, IL). Through-
out all of the experiments, number of cells, concentration
of DNA stain, and incubation time and temperature were
kept constant, to ensure reproducibility of DNA index (DI)
determination. Normal human lymphocytes were stained
by the same procedure, with each batch of fresh tumors
analyzed and run before the samples to calibrate the
instrument for the position of G0/G1 normal DNA-diploid
peak. The DI was determined according to Hiddemann et
al.28 Briefly, the DI was defined as the mode of the DNA
content of the G0/G1 cells of the sample divided by the
mode of the DNA measurement of the diploid G0/G1
reference cells. By definition, diploid cells have a DI of
1.0. Analogous results were obtained using fix and perm,
followed by RNase treatment or propidium  Nonidet
P-40 and RNase.
Tumor Cell Implantation
Animal studies were performed under a protocol ap-
proved by the Nevada Cancer Institute Animal Care and
Use Committee. Animals included nonobese diabetic
(NOD) mice and Cg-Prkdc scid Il2rg tm1Wjl/SzJ (severe
combined immunodeficiency ) mice (The Jackson Lab-
oratory, Bar Harbor, ME). For s.c. injection, cells were
resuspended in 100 L of PBS and injected s.c. into the
right flank of the animals. When s.c. tumors reached a
volume of 1 cm3, mice were euthanized and tumor, lungs,
and brain were collected for histological analysis, fixed,
and stained, according to standard techniques.Deep RNA-Seq
RNA sequencing (RNA-seq)–based mRNA profiling was
performed by Ocean Ridge Biosciences (Palm Beach
Gardens, FL), essentially as described by Bottomly et
al.29 Briefly, the Truseq RNA Sample preparation kit (Illu-
mina, San Diego, CA) was used to perform the following
sequential steps: i) isolation of polyadenylated mRNA
species, ii) synthesis of double-stranded cDNA, iii) end
repair of cDNA, iv) nucleotide addition to cDNA ends, v)
ligation of double-stranded adapters to the cDNA, and vi)
PCR amplification to select molecules containing adapt-
ers on both cDNA ends (Illumina). The amplified libraries
were pooled to load two index-tagged samples per lane,
diluted to a concentration of 12 pmol/L, and applied to a
flow cell using the Cluster Station (Illumina). The genera-
tion of clusters on the flow cell was performed using the
Cluster Station and Cluster Generation Kit version 5. Se-
quencing was performed on the GAIIX Sequencer with
Paired-End Module (Illumina), using version 5 sequenc-
ing kits and protocol 51  7 cycle Multiplexed Read 1,
which provided for 51 nucleotide single-end reads with
decoding of the six-nucleotide multiplex adapter se-
quences. Image analysis and base calling were per-
formed on the instrument using RTA software version 2.9
(Illumina). Demultiplexing, trimming, and alignment to the
Human Genome reference sequence (Human National
Center for Biotechnology Information build 37.2) were
conducted using CASAVA version 1.8 software (Illumina).
The raw results consisted of 21 to 33 million 49-nucleo-
tide reads per sample, with an average quality score of
35. CASAVA version 1.8 software was also used for align-
ment to the exon model and generation of gene-level
counts and single-nucleotide polymorphism (SNP) calls.
Gene Expression Analysis Using RNA-Seq Data
A total of 11,970 of a possible 23,890 Entrez ID genes
were selected as expressed based on the criteria that
2450 nucleotides of sequence were mapped to that
gene in two or more samples. To normalize the data, the
raw nucleotides mapped for each gene X sample were
converted to reads per 100,000 total reads. Missing data
points, in which no reads were mapped for a specific
sample X gene, were replaced with a value of 0.08 reads/
100,000 total reads. Fold changes were calculated for
each specific sample comparison for every gene, in
which at least one of the two samples met the threshold of
2450 nucleotides of mapped sequences. Otherwise,
fold changes were not reported.
SNP Analysis Using RNA-Seq Data
Illumina CASAVA 1.8 software reports the diploid geno-
type and quality score for each nucleotide position within
an mRNA, where the sample sequence differs from the
reference sequence. The list of SNP loci was filtered to
select for only SNPs with a Q score of75 in one or more
samples. Redundancy was removed to generate a
unique list of 37,622 SNPs, and the data were reformatted
to produce a table in which each row contained a unique
expres
20 m
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sample given in columnar format. For comparison of the
SNP genotypes of putative fusion hybrids to the parental
cells MA11 and MSC genotypes, we selected 434 loci
that had a high-quality score (Q  75) for both parents,
differed between the parents, and also had a high SNP
quality score for putative fusion hybrids and two refer-
ence cell lines. For comparison of SNP genotypes of
putative fusion hybrids to the parent cell MDA and MSC
genotypes, we selected a total of 441 SNP loci using
Figure 1. Spontaneous formation of proliferating heterotypic hybrids (with
points, of a co-culture of human MDA-DsRed (red) and MSC-EGFP (green) in
cells with a fibroblastic shape (yellow; arrows). B: Fluorescent micrographs
MDA-DsRed or MA11-DsRed (red), showing apparent involvement of cell ly
hybridization between breast carcinoma cells (MA11-DsRed and MDA-DsRed
were co-cultured for 3 days with MSC-luc, seeded at 3000 cells/cm2, and the
number of red hybrid cells was then assessed by flow cytometric analysis and
the mean  SD from two experiments. D: Plot of the percentage of cells mig
coated with a cell matrix–resembling preparation (Matrigel) for each of the
Matrigel-migrating cells on total cells migrating through noncoated control in
fixed with 4% paraformaldehyde for 20 minutes and then stained with DAP
per insert. Original magnification, 100. Data represent the mean  SD of th
to 3-day exposure to different concentrations of puromycin, measured by
(indicated in parenthesis as mean  SD) revealed acquisition by the hybrid
t-test, the difference between the hybrid cells and the parental breast cance
puromycin. F: 1-Integrin immunofluorescences on puromycin-selected c
revealing the hybrid nature of the puromycin-selected cells that, in addition to
on the cell surface. Nuclei stained with DAPI (blue). Scale bars: 50 m (A);similar criteria. Among the selected high-quality SNPcalls, the number of diploid matches (ie, both alleles)
sequence matches between a potential fusion hybrid or
reference cell line and each of the parent cell lines was
counted, and these counts were binned by chromosome.
Luciferase Assay
The preparation of cell extracts and measurement of lucif-
erase activity were performed using the Steady-Glo Lucif-
erase Reporter Assay System, according to recommenda-
by breast carcinoma cells. A: Fluorescent micrographs, at successive time
nce of puromycin, showing formation of double-labeled proliferating hybrid
points spaced by 3-hour intervals, of co-cultures of MSC-EGFP (green) with
ws) in the interaction of breast cancer cells with MSCs. C: Quantification of
C-luc in high-density co-culture. The tumor cells, seeded at 15,000 cells/cm2,
mor cell hybrids selected by 5-day exposure to puromycin (1 g/mL). The
ed as a percentage over the total of puromycin-resistant cells. Data represent
rough polyethylene terephthalate membrane cell culture inserts (8-m pore)
ast cancer cell lines used in the study. Data are expressed as percentage of
mbranes in 24 hours. The cells on the lower surface of the membranes were
umber of cells was counted in 8 to 12 randomly selected microscopic fields
our experiments. E: Sensitivity of parental breast carcinoma and hybrid cells
olium-based cell proliferation assay. The units of luciferase (luc) per cell
luciferase expression and puromycin resistance from MSC-luc; by Student’s
as statistically significant (P  0.01) in the range from 0.1 to 20 g/mL of
an MSC-luc-MA11-EGFP co-culture and on parental breast cancer cells,
sing EGFP (green), display high expression of the mesenchymal marker (red)
(B); 25 m (F). *P  0.01 using the Student’s t-test.MSCs)
the abse
, at time
sis (arro
) and MS
MSC–tu
express
rating th
two bre
sert me
I. The n
ree to f
a tetraz
lines of
r cells w
ells fromtions by the manufacturer (Promega, Madison, WI). The
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luminometer (Turner Biosystems, Sunnyvale, CA).
Immunocytochemistry
Cells were plated onto poly-L-lysine–coated chamber
slides, fixed in 4% paraformaldehyde, washed with PBS,
permeabilized in 0.2% Nonidet P-40, and blocked with goat
serum. After washing with PBS, cells were incubated over-
night at 4°C with a 1:100 dilution of anti-human CD29 anti-
body (Chemicon, Temecula, CA) in 1% bovine serum albu-
min–PBS, followed by a 45-minute incubation at room
temperature with tetrarhodamine isothiocyanate–labeled
secondary antibody (1:300; Jackson Immunoresearch,
West Grove, PA) in 1% bovine serum albumin in PBS. Cell
nuclei were labeled with DAPI (1:1000; Sigma-Aldrich, St.
Louis, MO), and cells were viewed under a CKX41 fluores-
cence-inverted microscope (Olympus, Center Valley, PA).
IHC Data
Sections (4 m thick) were incubated with mouse anti-pan
keratin monoclonal PM011 AE1-AE3 antibody, followed by
the MACH 4 universal two-step detection method, and la-
beled with horseradish peroxidase, as recommended by
the manufacturer (Biocare Medical, Concord, CA).
Results
Spontaneous Formation of MSC–Breast Cancer
Hybrids
We established co-cultures of human MSCs, derived
from bone marrows of healthy adult donors,30 with human
MDA or MA11 breast carcinoma cells at a 1:1 ratio (total
initial cell density, 1300 cells/cm2). The MSCs and breast
carcinoma cells were fluorescently tagged by retroviral
transduction with EGFP and DsRed-expressing vec-
tors,25 respectively. In co-culture, after 24 hours, we ob-
Table 1. Ploidy Reduction in Heterotypic Breast Cancer Hybrid
Cells in Culture
Cells
DNA index
D0 D60
MSC 1.0  0.1 0.9  0.1
MA11 2.2  0.2 2.2  0.1
MDA 1.3  0.1 1.3  0.1
Hybrid
MSC-MA11 3.2  0.2* 2.5  0.2
MSC-MDA 2.4  0.1* 1.5  0.1
Cells were fixed with 70% ethanol, stained with propidium iodide,
and analyzed by flow cytometry, as described in Materials and Meth-
ods. The cell content of DNA was measured at D0 and D60. Values are
the mean  SD from three experiments; the values indicated for the
hybrids were similar in five clones.
*Statistically significant difference by Student’s t-test with respect to
the corresponding values by the parental tumor cells (P  0.01).
D0, immediately after the end of puromycin selection of the hybrids;
D60, 60 days after the end of puromycin selection of the hybrids.served invasion of MSCs by breast cancer cells, resultingin cells with dual-fluorescence and mesenchymal mor-
phological characteristics (Figure 1, A and B). In several
cases, the dual-fluorescence cells were able to divide
(Figure 1A). To select heterotypic hybrids, we estab-
lished co-cultures of MSCs with MDA-DsRed or MA11-
EGFP cells under conditions favoring the growth and
identification of hybrids. For these experiments, MSCs
were chemiluminescently tagged and rendered puromy-
cin resistant (MSC-luc) by lentiviral transduction. The tu-
mor cells, seeded at 15,000 cells/cm2, were co-cultured
for 3 days with MSC-luc, seeded at 3000 cells/cm2; the
MSC–tumor cell hybrids were selected by exposure to 1
g/mL puromycin, which caused complete disappear-
ance of breast carcinoma cells. After 5 days of selection,
80%  14% (SD) of cells in MDA-MSC co-cultures were
fluorescent hybrids, versus 30%  15% (SD) of cells in
MA11-MSC co-cultures, as assessed by flow cytometry
(Figure 1C). Interestingly, the different capacity of MDA
and MA11 to form hybrids with MSC corresponded
roughly to the different capacity of the two breast cancer
cell lines to invade Matrigel, a substance mimicking the
basement membrane (62%  19% versus 15%  12%
for MDA and MA11 cells, respectively) (Figure 1D).
Characteristics of MSC–Breast Cancer Hybrids
At 2 to 3 weeks after the end of puromycin treatment, we
isolated puromycin-resistant fluorescent hybrids by fluo-
rescence-activated cell sorting. Independently derived
hybrid cell lines and their clones, isolated by limiting
dilution, displayed mesenchymal morphological charac-
teristics (see Supplemental Figure S1 at http://ajp.
amjpathol.org), an increase in DNA content (Table 1),
expression of luciferase (Figure 1E), resistance to puro-
mycin (Figure 1E), and high-level expression of 1-integ-
rin (CD29), a stromal marker not expressed or expressed
at lower levels in breast cancer cells (Figure 1F). The
growth kinetics of the MSC-luc-MA11-EGFP hybrid cell
lines and clones were not different from parental MA11-
EGFP cells, whereas it was heterogeneous for MSC-luc-
MDA-DsRed cell lines and clones, with doubling times
ranging from 22 to 55 hours (see Supplemental Figure
S2, A and B, at http://ajp.amjpathol.org). At 4 weeks after
Figure 2. Breast carcinoma cells undergo spontaneous homotypic hybrid-
ization, producing cells that continue proliferating. Micrographs of double-
labeled (EGFP  DsRed) MA11 cells derived from a co-culture of MA11-
EGFP (green) and MA11-DsRed (red). Images, taken at 3-day co-culture (D0)
and 7 days later (D7), reveal rapid proliferation of yellow hybrid cells. Scale
bar  50 m.
d alone
h respe
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and MSC-MDA hybrids, respectively, corresponding
roughly to the sum of the DI of MA11 (2.18) or MDA (1.25)
and of MSC (1.0) (Table 1). The difference in DI between the
parental breast carcinoma cell lines and their respective
hybrids was statistically significant (unpaired Student’s t-
test, P  0.01). MSC-MA11 hybrid clones had a heteroge-
neous DI, ranging from 2.72 to 4.7, whereas for MSC-MDA,
the DI ranged from 1.88 to 2.02 (Table 1). No correlation
was observed between the DI and the proliferation rate of
the individual hybrid clones.
Intrinsic Fusogenicity of Breast Cancer Cells
In 1:1 co-cultures of MA11-EGFP with MDA-DsRed and of
MA11-EGFP with MA11-DsRed, we observed, after 24 to
48 hours, the formation of dual-fluorescence hybrid cells.
Figure 2 shows an actively proliferating clone of dual-
fluorescence MA11-MSC hybrids.
Tumorigenic and Metastatic Properties of
Hybrids
Both MA11-MSC and MDA-MSC hybrids were tumori-
genic on s.c. injection in NOD. Cg-Prkdc scid Il2rg tm1Wjl/
SzJ (scid ) mice (Table 2). By using tumor cell inoculum
levels resulting in approximately 80% tumorigenicity for
both parental breast carcinoma cell lines, we observed
that the tumorigenicity of the hybrids was not significantly
Table 2. Tumorigenic and Metastatic Potential of MSC-Breast Ca
Type of tumor
105
MA11
s.c. Tumor 4/5 (80)
Lung metastasis 0/5
Data are given as number/total (percentage). Control MSCs implante
*Statistically significant difference by two-sided Fisher’s exact test witdifferent from parental breast cancer cells. To examine
the capacity of MDA hybrids to form metastasis to the
lung in NOD/scid  mice, 5  105 cells of six MDA-
DsRed-MSC-luc clones, derived by limiting dilution from
two independently derived hybrid cell lines, and six MDA-
DsRed clones, derived from parental cells, were im-
planted s.c. in the right flank (five animals per group). The
clones for the in vivo study were selected on the basis of
their doubling times in culture (between 22 and 26
hours). Mice were sacrificed when tumors reached a
volume of 1.0 cm3. All lungs were examined for metas-
tasis by analyzing 10 stepwise H&E-stained sections
(4-m thick). Statistically significantly more mice im-
planted with MDA-DsRed-MSC-luc clones than with
MDA-DsRed clones developed lung metastases (73%
versus 10%; P  0.01) (Table 2). Also, 7 of the 10 mice
implanted with MDA hybrid clones and examined his-
topathologically for brain metastases were found pos-
itive, whereas no brain metastatic foci were found in 10
mice implanted with MDA-DsRed clones. Consistent
with previous reports,31 human MSCs, untransduced or
transduced with pCignal-luc, were not able to form
tumors and/or metastases on s.c. injection in immuno-
deficient mice.
Hybrids Acquire Mesenchymal Characteristics
In view of the increased metastatic capacity of MSC-luc-
MDA-DsRed hybrids, we next investigated whether they
Figure 3. Enhanced motility of MSC-MDA hybrids with re-
spect to parental MDA. Phase-contrast images, spaced by 10-
hour intervals, of pipet tip–wounded monolayers of MDA and
MSC-MDA heterotypic hybrids in a tissue culture–treated poly-
styrene plate, showing that the hybrids, similar to parental
MSC (data not shown), polarize toward the wound, initiate
protrusion, and migrate faster than parental breast carci-
noma cells, closing the wound during the time course. Scale
bar  100 m.
a Hybrids
Inoculum of cells
5  105
ds MDA Hybrids
4) 25/30 (83) 27/30 (90)
3/30 (10) 22/30 (73)*
into 10 mice (inoculum, 500,000 cells/mouse) were nontumorigenic.
ct to the rate of metastasis by MDA (P  0.001).rcinom
Hybri
6/11 (5
0/11
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are equipped with motor proteins that enable them to
migrate during the development throughout embryonic
regions.32 In wound-healing assays, we observed that
MSC-luc-MDA-DsRed hybrids closed the gap much
faster than parental breast cancer cells. Sequential mi-
crographs from a representative experiment are pre-
sented in Figure 3.
To evaluate whether fusion with MSCs resulted in
increased expression of mesenchymal genes, we an-
alyzed the global gene expression profiles of an MSC-
luc-MDA-DsRed tumor xenograft and its brain metas-
Figure 4. Mixed pattern of gene expression of heterotypic hybrids. Heat maps for
MSC-MDA hybrids (from s.c. tumor and metastasis), MSC, and MDA, showing
clustered gene-level counts with lower than median (green), higher than median
(red), and median (black) levels of expression. Each row represents a single gene.
Clusteringwas performed using centered correlation as distancemeasure and single
linkage as method.tasis and compared them with parental MDA-DsRed
xenografts and with MSC-luc. To this aim, xenografts
and brain metastasis were dissociated, separated from
contaminating host cells by fluorescence sorting, and
cultured for 3 to 4 days. Their global gene expression
profile was analyzed by RNA-seq. The gene expres-
sion profile of the hybrids was consistent with their
derivation from both parental partners (Figure 4). On
average, 1239 and 5345 genes were differentially ex-
pressed between MDA hybrid and MDA and between
MDA hybrid and MSC, respectively; 1320 and 5297
genes were differentially expressed between MDA hy-
brid brain metastasis and MDA and between MDA
hybrid brain metastasis and MSC, respectively. Inter-
estingly, significant changes in biochemical pathways
between MDA hybrid and MDA tumor xenografts were
detected by the Kyoto Encyclopedia of Genes and
Genomes pathway analysis for cytokine-cytokine re-
ceptor interaction: 21 genes overexpressed in the hy-
brids/91 total; P (P value indicating the significance of
enrichment calculated from a hypergeometric test) 
5.37e-08, with extracellular matrix-receptor interaction
(12/59; P 3.17e-05), focal adhesion pathways (22/31;
P 7.09e-06), and cell adhesion molecules (13/14; P
5.91e-06). Also, several mesenchymal genes33 were
overexpressed in hybrids compared with the respec-
tive parental MDA cells, including secreted protein,
acidic, cysteine-rich (SPARC), fibronectin, and CD109
(see Supplemental Table S1 at http://ajp.amjpathol.
org). Interestingly, expression of the aldehyde dehy-
drogeanse (ALDH) 1A3 isoform, the main ALDH iso-
form in breast cancer stem cells,34 was increased 10-
Figure 5. Increased frequency of multipolar (tripolar/tetrapolar) mitosis
after hybridization. A: Tripolar (left panel) and tetrapolar (right panel)
metaphases in MSC-MA11 hybrid cells revealed by DAPI staining of
DNA (blue). B: Immunofluorescence for -tubulin (red), revealing the
multipolar configuration of the mitotic spindle in an MSC-MA11-EGFP
breast carcinoma hybrid cell. Condensed chromosomes stained with DAPI
(blue). C: Graph depicting the percentage of multipolar mitosis in the
hybrids of breast carcinoma cells with MSC and the parental tumor cells,
showing twofold to threefold greater multipolar mitosis in the heterotypic
hybrids. Data represent the mean  SD from three experiments, each one
consisting of 100 metaphases plus anaphases analyzed per cell type. In
parental MSCs, no multipolar mitosis was detected. Scale bar  20 m.fold in an MDA hybrid tumor xenograft, and its brain
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(17.4- and 13.4-fold, respectively).
Hybrids Are Genetically Unstable
After 3 months in culture, a generalized decrease in DNA
ploidy was observed for both MSC-MA11 and MSC-MDA
hybrids (Table 1). The decrease in ploidy occurred even if
puromycin-selective pressure was constantly maintained. A
similar decrease in DNA ploidy was also observed during
growth of tumor xenografts. Multipolar metaphases and un-
equal divisions with lagging DNA, suggestive of ploidy re-
duction, were observed in the hybrid cultures (Figure 5A).
Interestingly, multipolar mitoses were also observed in ho-
motypic hybrids and, at a lower frequency (P 0.05), in the
Figure 7. In vivo reversion of MSC–breast carcinoma hybrid cells from fibr
IHC for keratin (middle panel), and immunofluorescence for EGFP (righ
MSC-MA11-EGFP hybrid cells, showing expression by the tumor cells of bo
in the fluorescence micrograph. B: Tumor xenograft explant of MSC-MA11
smaller nuclei. Nuclei stained with DAPI (blue). C: Immunofluorescences for
tumor and 3 days of ex vivo culture, and an explant of parental MA11-EGFP c
and epithelial morphological characteristics, in contrast to parental cells (re
parental MA11 cells (left panel) displaying similar breast cancer–like morphologica
(C and D).parental breast carcinoma cell lines, but not in parental
MSCs (Figure 5, B and C).
Hybrids Reacquire Breast Cancer–Like
Morphological Characteristics in Culture and
in Vivo but Maintain a Mixed Gene Expression
Profile
In most cases, a transition from mesenchymal to epi-
thelial-like morphological characteristics was observed
in culture within 3 months (Figure 6). However, all hy-
brids maintained, to a variable extent, puromycin re-
sistance and luciferase expression (data not shown).
The phenotypic reversion of hybrids to a breast carci-
Figure 6. Reversion of the fibroblastic morpho-
logical characteristics of the MSC-MA11 hybrid
cells to an epithelial, breast carcinoma–like ap-
pearance. A: Micrographs separated by an inter-
val of 90 days of an MSC-MA11 hybrid line in
culture showing that the fibroblastic morpholog-
ical characteristics of the cells reverted, within
that period, to an epithelial shape. B: Spontane-
ous formation of islets of cells with breast can-
cer–like epithelial morphological characteristics
(single asterisk) in four different MSC-MA11
hybrid lines in culture, which, since being
formed, were composed only by fibroblast-like
cells (indicated by double asterisks). The mor-
phological changes occurred in both the pres-
ence and the absence of puromycin. Scale bars:
50 m (A); 100 m (B).
ke to epithelial morphological characteristics. A: H&E staining (left panel),
l) on tissue sections of a tumor produced in mice by s.c. implantation of
(green) and the epithelial marker, keratin. Nuclei stained with DAPI (blue)
ells reverting from fibroblastic cells with large nuclei to epithelial cells with
rin on MSC-MA11-EGFP hybrid cells (right panel), after growth as xenograft
t panel), showing positivity of heterotypic hybrid cells with both fibroblastic
xplants of tumor xenografts of MSC-MA11 hybrid cells (right panel) andoblast-li
t pane
th EGFP
hybrid c
1-integ
ells (lef
d). D: El characteristics in ex vivo culture. Scale bars: 40 m (A); 25 m (B); 50 m
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ex vivo culture is shown in Figure 7. Tumor hybrid
xenografts were all homogeneously EGFP or DsRed
and formed poorly differentiated adenocarcinomas
with high-grade features and a variable extent of ne-
crosis; different from parental xenografts, some of the
tumor hybrids showed differentiated features, such as
nesting and more cohesive formations (Figure 7). None
of the hybrid xenografts had the typical fusiform cell
shape and fascicular cellular arrangement character-
istic of malignant tumors of mesenchymal origin (fibro-
sarcomas). Strong diffuse membranous expression of
AE1-AE3 cytokeratin in xenografts (Figure 7A), compa-
rable with the expression in parental breast carcinoma
xenografts, and cell morphology (Figure 7, B and D)
were suggestive of the epithelial nature of the tumors,
whereas expression of 1-integrin (CD29) (Figure 7C)
and luciferase expression suggested an MSC contri-
bution to the hybrid phenotype. To evaluate whether
tumors were transplantable, and to exclude that lucif-
erase activity was the result of contaminating MSC-luc,
tumors were disaggregated and cultured for 1 week;
106 cells were re-injected s.c. into NOD/scid  mice.
After 3 to 4 weeks, 1-cm3 tumors were formed that, on
dissociation, expressed EGFP and luciferase; the tu-
mors maintained high-level resistance to puromycin
(data not shown). Their DI (range, 2.1 to 2.6) was
similar to that of parental MA11 cells.
Genetic Contribution of Both Parental Partners
to Hybrid Xenografts and Metastasis
We used analysis of coding SNPs to investigate the
Figure 8. Genetic contribution from both breast carcinoma and MSC to
heterotypic hybrids. Comparative SNP analysis between either MSC-MDA or
MSC-MA11 hybrids (after growth in mice as xenograft tumors) and their
specific parental partners. The 441 and 434 loci differing between the two
parental cell types were analyzed for MSC-MDA and MSC-MA11 hybrids,
respectively.genetic contribution of MSCs and breast cancer cellsto both MA11 and MDA tumor xenografts and to MDA
metastasis. As shown in Figure 8, we analyzed coding
SNPs in an MSC-luc-MA11-EGFP xenograft and found
SNPs from both parental partners in almost all chro-
mosomes. In the hybrid tumor xenograft, 55% of the
434 SNP loci, which differed between the parental part-
ners, derived from MA-EGFP and 45% derived from
MSC-luc. In both MSC-luc-MDA-DsRed tumor xeno-
graft and its brain and lung metastasis, 77% of SNPs
derived from MDA-DsRed and 23% derived from MSC-
luc (Figure 8). The SNPs of MDA brain and lung me-
tastases were identical.
Discussion
Herein, we demonstrate that generation of breast can-
cer–MSC hybrid variants represents a large-scale
mechanism of genotypic and phenotypic diversifica-
tion. High-frequency spontaneous formation of hybrids
was surprising, particularly in view of the apparently
chaotic nature of aneuploidy.14 One argument against
the relevance of heterotypic fusion in cancer progres-
sion is the lack of evidence that, during progression,
cancer cells become tetraploid.35 Our observation that
breast cancer–MSC hybrids undergo multipolar divi-
sions and quickly become aneuploid suggests a logi-
cal explanation for this apparent discrepancy. Interest-
ingly, multipolar mitoses were observed in cultures of
MA11 and MDA cells, although at a lower rate, but not
in MSCs; accordingly, we observed spontaneous for-
mation of tumor-tumor hybrids, suggesting that homo-
typic, in addition to heterotypic, fusion may contribute
to breast cancer heterogeneity. These data are in
agreement with recent reports of acquisition of a dual-
metastasis organotropism through spontaneous fusion
between MDA variants.36 In the present study, we ob-
served invasion of MSCs by breast cancer cells, with a
correlation between the invasive capacity of breast
cancer cells (measured as the capacity to migrate
through Matrigel) and the frequency of formation of
hybrids. The active role played by breast cancer cells
in the heterotypic hybridization is supported by the
observation of formation of homotypic hybrids for both
MA11 and MDA cells.
Clearly, the genome of the breast cancer cells con-
tributed tumorigenicity to the hybrids, whereas MSCs
contributed expression of mesenchymal genes and, in
case of MDA hybrids, increased metastatic potential.
As xenografts, and with time in culture, the mixed ex-
pression of mesenchymal and breast carcinoma genes
was maintained, whereas the morphological character-
istics of hybrids became similar to those of the paren-
tal breast cancer cells. Interestingly, in a previous
study,37 although tumors formed in mice by human
fibroblasts cotransduced with E1A and V-Ha-Ras had a
histopathological appearance of fibrosarcomas, tu-
mors formed by fibroblast hybrids had an epithelial-like
appearance. Instead, malignant transformation of nor-
mal mouse stroma–derived cells by fusion with breast
cancer epithelium resulted in spindle-shaped fibro-
Formation of MSC–Breast Cancer Hybrids 2513
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mas.38 Our data are consistent with previous re-
ports39,40 that spontaneously fused bone marrow cells
can subsequently adopt the phenotype of the recipient
cells. The expression of genes from both parental part-
ners in the MDA-MSC hybrid cells is in agreement with
previous findings41,42 in human melanoma–mouse
macrophage hybrids. Analysis of coding SNPs in xe-
nografts confirmed their mixed MSC–breast cancer
genetic background. Overexpression of mesenchymal
genes, such as SPARC,43,44 indicates that breast can-
cer cells may acquire mesenchymal markers by EMT
and by fusion with MSCs; in particular, SPARC has
recently been associated with the most aggressive and
highly metastatic tumors.45 Up-regulation of SPARC
was previously observed by Chakraborty et al46 in
macrophage-melanoma hybrids. Interestingly, a sub-
group of breast cancer cell lines with enhanced inva-
sive properties and a predominantly mesenchymal
gene expression signature has recently been identi-
fied.47 Mesenchymal markers were reportedly overex-
pressed in circulating tumor cells of patients with met-
astatic breast cancer,48 and residual breast cancer
cells surviving after conventional therapy displayed
mesenchymal features.49 It is intriguing that ALDH1A3,
the main ALDH isoform in breast cancer stem cells,
which is reportedly predictive of breast cancer metas-
tasis,34 was increased by 10-fold in MDA hybrid tumor
xenografts and its brain metastasis compared with pa-
rental MDA xenografts.
Spontaneous fusogenic events between normal stroma–
derived cells of mouse mammary glands and mam-
mary cancer cells embedded in the stroma have been
previously described.38 The capacity of MSCs to mi-
grate to the site of breast cancer growth,6 and the
observation that conditioned medium of breast cancer
cells, including MDA, contains signaling molecules
that induce MSC chemotaxis,50 reinforces the clinical
relevance of the formation of MSC–breast cancer hy-
brids in the breast. We speculate that these fusogenic
events may also occur at metastatic sites, involving a
direct interaction between MSCs of the metastatic site
and the migrated breast cancer cells. In this case, the
hybrid cells may acquire properties from local MSCs
that allow them to successfully implant and proliferate
at the metastatic site.
Both in vitro and in vivo, DNA ploidy decreased. The
decrease was not due to the withdrawal of the select-
ing agent, because it occurred in hybrid cultures con-
stantly maintained in the presence of puromycin, and
did not result in a reversal of the mixed phenotype, as
indicated by RNA-seq of xenografts, by immunohisto-
chemistry (IHC) data, and presumably by the acquisi-
tion of a metastatic phenotype for MSC-MDA hybrids.
In agreement with our data, previous analysis of the
ploidy pattern of primary breast carcinoma and corre-
sponding metastatic nodes revealed a much higher
incidence of moderate aneuploidy in the metastatic
nodes.51 The highly metastatic phenotype that we ob-
served in many MSC-MDA hybrid xenografts suggests
that MSC–breast cancer fusion is a potential mecha-nism of tumor progression. Clearly, not all hybrid cells
are tumorigenic and/or have enhanced promalignant
properties. In particular, we did not observe formation
of metastasis on s.c. implantation of MA11 hybrids. It is
conceivable that cell heterogeneity translates in vivo into
selection of clones with survival advantages toward ad-
verse conditions in the body and/or to chemotherapeutic/
radiotherapeutic treatments. Studies of breast cancer–MSC
fusion in vivo are warranted to fully evaluate the clinical
relevance and frequency of this phenomenon. Our find-
ings suggest that targeting one or more of the following
may prevent acquisition of a more malignant phenotype
and/or breast cancer spreading to distant organs: i) fu-
sion process, ii) early and rate-limiting post-fusion events,
and iii) mesenchymal gene products. The possibility that
MSCs are also implicated in the early phase of tumori-
genesis cannot be excluded: initial mutagenic events
may act synergistically with the acquisition by fusion with
MSCs of mesenchymal traits, such as surface antigen
expression, immune tolerance, or stem cell phenotypic
features, to allow local tumor growth.
In conclusion, our data show that breast cancer cell
fusion with MSCs generates a new hybrid offspring that
contributes to breast cancer cell heterogeneity with
unforeseen and possibly dangerous consequences.
Where such fusions form compatible genetic re-assort-
ments that allow the fusion to be productive, rather
than destructive, and acquire prometastatic traits,
breast cancer subpopulations with increased malig-
nancy are born.
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